Influence of genetic polymorphisms in glutathione-S-transferases gene in response to imatinib among Brazilian patients with chronic myeloid leukemia.
Sign Up to like & getrecommendations! Published in 2021 at "Molecular biology reports"
DOI: 10.1007/s11033-020-06093-z
Abstract: Polymorphism in metabolizing enzymes can influence drug response as well as the risk for adverse drug reactions. Nevertheless, there are still few studies analyzing the consequence of polymorphisms for the Glutathione-S-transferases (GST) gene to drug… read more here.
Keywords: cml patients; cml; response; response imatinib ... See more keywords
HIGH EXPRESSION WITH PD-1+ FOXP3+ ΓΔ T REGULATORY SUBSETS IN CHRONIC MYELOID LEUKEMIA PATIENTS
Sign Up to like & getrecommendations! Published in 2019 at "Experimental Hematology"
DOI: 10.1016/j.exphem.2019.06.462
Abstract: Objective Tyrosine kinase inhibitor (TKI) has achieved certain efficacy in treatment of chronic myeloid leukemia (CML), but there are still many cases of drug resistance and relapse. Anti-leukemia immunity of γδ T cells may play… read more here.
Keywords: expression; leukemia; cml patients; regulatory subsets ... See more keywords
Correlation of the transcription factors IRF4 and BACH2 with the abnormal NFATC1 expression in T cells from chronic myeloid leukemia patients
Sign Up to like & getrecommendations! Published in 2022 at "Hematology"
DOI: 10.1080/16078454.2022.2066245
Abstract: ABSTRACT Objective T cell dysfunction is a common characteristic of patients with myeloid leukemia and is closely related to clinical efficacy and prognosis. In order to clarify the mechanisms leading to the T cell dysfunction,… read more here.
Keywords: cells chronic; myeloid leukemia; irf4 bach2; transcription ... See more keywords
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
Sign Up to like & getrecommendations! Published in 2019 at "Oncoimmunology"
DOI: 10.1080/2162402x.2019.1638210
Abstract: ABSTRACT Changes in the immune system induced by tyrosine kinase inhibitors (TKI) have been shown to positively correlate with therapy responses in chronic myeloid leukemia (CML). However, only a few longitudinal studies exist and no… read more here.
Keywords: patients treated; cml patients; diagnosed cml; imatinib ... See more keywords
Past, present and future use of cytotoxic agents in oncology practice: A systematic review of Pubmed and ClinicalTrials.gov databases
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/1078155220951237
Abstract: comparable for expected response to SARS-CoV-2. Authors cite the work of Breccia et al. to claim that “there is no data suggesting that chronic phase CML patients are at higher risk of infection for SARS-CoV-2… read more here.
Keywords: cml patients; use; practice; sars cov ... See more keywords
Clinical efficacy of fecal occult blood test and colonoscopy for dasatinib-induced hemorrhagic colitis in CML patients.
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood-2016-08-734947
Abstract: A positive fecal occult blood test (FOBT) is occasionally observed in some chronic myeloid leukemia (CML) patients treated with a tyrosine kinase inhibitor (TKI), and hemorrhagic colitis in patients treated with dasatinib has been reported.… read more here.
Keywords: cml patients; induced hemorrhagic; patients treated; dasatinib ... See more keywords
The Evaluation of Residual Disease By Digital PCR, and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after for Stopping Imatinib First-Line in Chronic Phase CML Patients: Results of the STIM2 Study.
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-113029
Abstract: Background TKI discontinuation is now a critical goal of CML management and several studies have demonstrated the feasibility of stopping safely imatinib (IM). A sustained deep molecular response (DMR) on long-term TKI therapy seems critical… read more here.
Keywords: cml patients; ddpcr; abl1; duration ... See more keywords
One Size Does Not Fit to All: Intolerant or Resistant CML Patients Could Benefit from Different Ponatinib Starting Dose Strategies. Multicenter Italian Experience
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-116825
Abstract: Background: Ponatinib is effective as salvage treatment for chronic phase (CP) Ph+ chronic myeloid leukemia (CML) patients resistant or intolerant to prior TKIs. Based on the concern for an unfavourable cardiovascular toxicity profile, a dose… read more here.
Keywords: cml patients; starting dose; treatment; honoraria ... See more keywords
Optimum Imatinib Exposure Have Possibility of Leading to Appropriate Immune Response after Imatinib Discontinuation in CML Patients
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-130300
Abstract: Introduction: Imatinib, the first tyrosine kinase inhibitor (TKI), has dramatically improved the prognosis of chronic myeloid leukemia (CML) patients. Recently, many trials of TKI discontinuation revealed that approximately 40% to 60% of CML patients who… read more here.
Keywords: cml patients; stopping imatinib; research; research funding ... See more keywords
Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.
Sign Up to like & getrecommendations! Published in 2019 at "Blood advances"
DOI: 10.1182/bloodadvances.2018025874
Abstract: Cardiovascular or arteriothrombotic adverse events (CV- or AT-AEs) are reported in chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs). The incidence and characteristics across different TKI have not been systematically analyzed. We… read more here.
Keywords: aes; cml patients; cardiovascular arteriothrombotic; arteriothrombotic adverse ... See more keywords
Molecular prediction of chronic myeloid leukemia risk and resistance to imatinib.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.e18543
Abstract: e18543 Background: Chronic myeloid leukemia (CML) is characterized by the Bcr-Abl genetic translocation which leads to constitutive tyrosine kinase signaling. Treatment with tyrosine kinase inhibitors as imatinib eliminates CML cells, but resistance often occurs. No… read more here.
Keywords: myeloid leukemia; cml patients; imatinib; treatment ... See more keywords